FDA approves isatuximab-irfc for subcutaneous injection for multiple myeloma indications
Regulatoryapprovedisatuximab-irfcPositive
AI Analysis
Summary
FDA approves isatuximab-irfc for subcutaneous injection in multiple myeloma patients. This approval represents a regulatory milestone for the drug's new formulation.
Outcome Details
FDA approves isatuximab-irfc for subcutaneous injection for multiple myeloma indications
Importance:8/10
Sentiment:
0.85
FDA approvaloncologymultiple myelomamonoclonal antibody
Read the original article
Published by FDA Drugs (New Approvals & NDA) on July 10, 2026 12:00 PM